The outcome for some of the most common childhood cancers remains unacceptable and for those who survive, long-term medical complications of therapy are a reality.
While an empiric strategy of evaluation of chemotherapeutic agents has resulted in impressive gains in survival of children with cancer, it is clear that the constantly increasing number of new agents requires a strategy in which early phase clinical trails are developed only when justified by strong pre-clinical laboratory data.
Despite advances in the treatment of cancer, the outcome for some of the most common childhood cancers remains extremely poor. Our pediatric oncology program at Children’s Hospital and Regional Medical Center is committed to investigate how to best administer currently available chemotherapy agents and how to develop new therapies for these childhood cancers. A successful Phase I/II clinical trial program is essential to our mission of advancing treatment of pediatric cancer and providing options to families and patients fighting cancer.
Chris loves baseball – he has a history of playing for his high school team and is a longtime fan of the San Francisco Giants. However, when he was in high school, Chris began having strange symptoms. Today, Chris is a three-time survivor of glioblastoma.
